Tenaya Therapeutics (TNYA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on the stock and has a $18.00 price target.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Joseph Pantginis’s rating is based on the promising potential of Tenaya Therapeutics’ gene therapy, TN-401, which recently received notable financial backing. The company secured an $8 million grant from the California Institute of Regenerative Medicine (CIRM) to support its ongoing Phase 1b RIDGE-1 study. This funding is a significant vote of confidence, underscoring the promising future of the TN-401 program aimed at treating PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).
Additionally, Tenaya Therapeutics is making substantial progress in its clinical-stage pipeline, with plans to present new data across its programs in 2025. The company is set to continue delivering data on its TN-201 and TN-401 programs, with upcoming milestones expected to build on the positive initial results already achieved. These developments suggest a robust pathway forward for Tenaya, justifying the Buy rating given by Pantginis.
According to TipRanks, Pantginis is an analyst with an average return of -3.5% and a 30.54% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Cytokinetics, Esperion, and Lexicon Pharmaceuticals.